How a 56-year-old man used ChatGPT to drop 11 kg in just 46 days
In a video uploaded on May 17, Crone opened up about his dramatic transformation, revealing that he went from 209 lbs (95 kg) to 183.8 lbs (83 kg) with no shortcuts, no dietary restrictions, and no drugs, The Economic Times reported.
'I was ashamed of my physical health and knew I had to make a change,' Crone said in the video.
According to the report, the YouTuber turned to ChatGPT for help and used the platform to craft a routine based on his goals and lifestyle, the report said. Crone, a husband and father of two, said he created a disciplined and structured routine that included clean eating, consistent workouts, hydration, and a good sleep cycle.
The report said he ate just two meals, with a long fasting window and no eating after 5 pm. His meals included whole, nutrient-rich foods such as grass-fed meats, steel-cut oats, jasmine rice, olive oil, and greens. He completely cut off processed foods, seed oils, sugar, and dairy, focusing on high-quality, organic, hormone-free ingredients.
The report added that Crone also incorporated supplements in his daily routine, including creatine, beta-alanine, collagen, whey protein, and magnesium, to support his training and recovery. He woke up at 4.30 am every day, and exercised in his garage gym for 60 to 90 minutes six days a week. He worked on his sleep cycle, with no screens an hour before bed, blackout curtains, and the elimination of synthetic materials in his bedding. He also included a spoonful of local raw honey before sleep to support rest and recovery.
He prioritised natural light exposure every morning, drank nearly four litres of water daily, but stopped hydration by early evening, and ensured consistent, distraction-free sleep each night. His progress was tracked through daily weigh-ins, based on which ChatGPT adjusted the plan, the report added.
Crone said, the report added, his transformation did not rely on any weight-loss medications like Ozempic. 'No drugs, no shortcuts, just whole foods, water, exercise, and sleep,' he said.
Other than weight loss and a full-body reset, Crone said the regimen he followed reduced inflammation, improved his joint health, provided better mental clarity, and boosted his confidence.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
8 hours ago
- Time of India
‘ChatGPT helped me lose 27 kilos in 6 months': Man says after life-changing AI transformation
What started as a digital experiment turned into a radical health transformation for a YouTuber known for his channel My Life By AI. In a video posted on July 12, 2025, he revealed how using ChatGPT as a personal assistant helped him shed 27 kilograms (about 60 pounds) and regain control of his physical and mental well-being. Powered by a virtual AI coach he named Arthur, the six-month journey was driven by discipline, smart planning, and daily guidance from OpenAI's chatbot. He credits the system for rebuilding his health and his life. How AI helped break bad habits and build a weight loss routine Rather than using ChatGPT for simple queries, the YouTuber integrated it into his entire lifestyle, creating a virtual assistant named Arthur to manage everything from meals and workouts to his creative workflow. Initially, his weekends were filled with fast food indulgences—burgers, fries, beer—leading to guilt and setbacks. But with Arthur's daily check-ins, tailored exercise prompts, and AI-generated strategies like post-meal walks and craving substitutions, he gradually replaced those patterns with healthier also planned structured, nutritious meals and offered consistency he had long lacked. Over time, this AI-guided system transformed his health, mindset, and routine, proving crucial to his 27-kilo weight loss journey. What's on the plate: Clean, AI-guided eating Using ChatGPT, he replaced processed snacks with whole foods and balanced meals. His daily diet included: Breakfast: Scrambled eggs with Parmesan and toast Lunch: Chili beef, rice, and refried beans Dinner: Baked chicken, sweet kumara, grilled capsicum and courgettes, finished with Greek yogurt This AI-assisted meal planning ensured both nutrition and satiety without guesswork. Consistency Over Perfection 'The goal wasn't to be perfect. It was to be consistent,' he said. This mindset, reinforced by Arthur, helped him stick to his routine even on tough days. Whether it was walking several kilometers or logging meals, the AI system reduced decision fatigue and helped create long-term habits. Aside from the physical transformation, the man described notable improvements in energy, mood, and focus. The AI didn't just offer instructions. It became a support system. By reducing mental clutter, Arthur gave him space to be more present, creative, and resilient. For this YouTuber, AI isn't just a productivity tool. It is a lifestyle enabler. 'Letting AI run my life didn't make me perfect. But it made me consistent,' he said. His story offers a glimpse into a future where personal health, productivity, and wellness may be deeply intertwined with digital intelligence.
Time of India
16 hours ago
- Time of India
Weight loss drugs could improve polycystic ovary syndrome: All you need to know
Image credits: Getty Images According to the Endocrine Society, an estimated 5-6 million women of reproductive age in the U.S. are affected by PCOS, which is frequently underdiagnosed. Caused by high levels of testosterone and androgens, polycystic ovary syndrome leads to symptoms such as irregular periods, excess hair growth, acne, insulin resistance and more. It is one of the leading causes of infertility and is strongly linked to metabolic issues, leading to weight gain and hormonal imbalance. One would think a condition affecting such a huge number of women would have a treatment and medicine ready by now. However, when it comes to PCOS, a condition which also leads to other damaging conditions such as obesity and Type 2 diabetes, there's no standard treatment. Mostly, women opt for birth control, lifestyle changes and a diabetes drug, Metformin, which helps with some symptoms. However, now, a ray of light has come around in the form of popular weight loss drugs that are shockingly helping with improving PCOS. One of the many women who have experienced a positive result is Grace Hamilton, 27, who earlier had to battle problems like hair loss, heavy periods, inconsistent menstrual cycles, mental health problems and sudden weight loss. After getting diagnosed with PCOS, she tried birth control and lifestyle changes, only to see limited improvements. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas in Dubai | Search Ads Get Info Undo It was in 2024 when Hamilton joined a trial examining the effects of GLP-1 drugs in PCOS patients. In October, she received her first dose of semaglutide, the active ingredient in Wegovy and Ozempic. The results, as she said to CNBC were almost immediate with resumed periods, hair regrowth and improvement in depression and anxiety. 'I'm so glad that I stuck with it because it was just clear as day that it was the missing link for me,' said Hamilton, adding that she also maintained a diet and exercise regimen. Are weight loss drugs really the answer? Image credits: Getty Images Some health experts see huge potential in GLP-1, particularly in their effect on improving weight loss and insulin sensitivity. 'The unmet need is massive,' said Dr. Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado, to CNBC. 'Primary therapies used for PCOS symptoms haven't changed in nearly 50 years.' Cree has been studying the effects of GLP-1 in adolescents with PCOS for more than 10 years. She previously studied the oral form of semaglutide and now has an ongoing clinical trial with the injectable version, which worked well for patients like Hamilton. Her trial began in 2023 with girls and women between the ages of 12-35 with obesity and PCOS who are on or off Metformin. Semaglutide was administered to the patients for 10 months to analyse their weight loss, metabolic changes and reproductive functions. The initial data included 11 women who completed the 10-month trial and were not on Metformin. 8 of these lost more than 10% of their body weight and saw a reduction in their hormone levels. Six of the 8 women even reported more regular periods. However, her study group is much smaller compared to the studies done on the popular weight loss drugs, and the results did not show similar effects on everyone. Here, the importance of conducting larger and longer trials on the same is important. This is because the potential for GLP-1 to cause relief in various PCOS symptoms remains. In previous studies, it has been found that in adults with PCOS, losing even 5% of body weight can improve insulin sensitivity. Thus, the body can respond better to insulin, and the pancreas doesn't need to pump out more insulin to keep the blood sugar in check. This will lower insulin levels, in turn lowering the production of testosterone and reducing symptoms of irregular period, acne and excess hair growth. Semaglutide not only improves insulin sensitivity but also reduces appetite by slowing how quickly the food leaves the stomach, prompting the pancreas to release insulin when the blood sugar is high and suppressing the release of a hormone that elevates blood sugar. Not only trials, a recent survey of 1700 people by the birth control app Natural Cycles, revealed that 64% of women with PCOS who took GLP-1 reported more predictable periods, and 20% reported that their bleeding days were shorter. Now, what is needed is a much larger research study on the subject to analyse its effects and see if it can be administered to all women with PCOS.
Time of India
a day ago
- Time of India
Ozempic and Wegovy may cut dementia risk by 45% and manage diabetes, study finds
Source: Reuters A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro- may significantly reduce the risk of developing dementia. The analysis, conducted by Irish researchers and published in JAMA Neurology , involved data from over 164,000 participants and found that these medications reduced the risk of memory-robbing disorders by up to 45 per cent. These findings not only open new avenues for neurological protection but also position GLP-1 drugs as powerful tools in both metabolic and cognitive health management. Study links GLP-1 drugs like Ozempic and Mounjaro to lower dementia risk Researchers from the University of Galway reviewed 26 clinical trials involving 164,531 individuals—65% of whom were men, with an average age of 64. The participants were followed for an average of 31 months. The key discovery: patients taking GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were 45% less likely to develop dementia compared to those on other glucose-lowering medications. Dr. Catriona Reddin, senior study author, said, 'Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo How GLP-1 agonists may protect against dementia Although the exact mechanism remains under investigation, researchers propose several pathways through which GLP-1 medications could shield the brain: Reduced neuroinflammation: These drugs may lower inflammation in the brain, which is known to damage neurons and trigger dementia symptoms. Decrease in amyloid and tau proteins: GLP-1 agonists could suppress the accumulation of toxic proteins linked to Alzheimer's disease. Improved blood vessel health: They may reduce blood pressure and enhance blood flow, preventing vascular dementia. Neurogenesis stimulation: Early research suggests these drugs may promote neural growth in the hippocampus, the brain region essential for memory. GLP-1 drugs may help prevent both diabetes and dementia The new study aligns with earlier research from the University of Florida, which followed 400,000 Americans and reported a 33% lower risk of dementia among GLP-1 users compared to other treatments. This growing body of evidence supports the role of semaglutide and tirzepatide not only in treating type 2 diabetes and obesity but potentially in preventing cognitive decline. Professor Martin O'Donnell, Dean at the University of Galway, emphasised, 'With both diabetes and dementia rising, these findings have major public health implications.' Dementia and diabetes: Twin epidemics in the US The study arrives amid alarming trends: Over 8 million Americans currently live with dementia, with 500,000 new cases diagnosed each year. Diabetes now affects 38 million people in the US; around 12% of the population. According to the Alzheimer's Association, Alzheimer's rates have climbed 25 consecutive years. The intersection of these two epidemics highlights the urgency of therapies that can address both conditions simultaneously. Study highlights need for more GLP-1 brain health data While the findings are promising, researchers caution that more work is needed to confirm the results. Notable limitations include: Lack of data on dementia subtypes like Lewy body and vascular dementia Differences in study design and follow-up durations Unclear long-term cognitive outcomes for different age groups and genders Still, this analysis lays essential groundwork for future research into neurometabolic protection via GLP-1 therapies. Originally celebrated as breakthrough treatments for obesity and diabetes, these medications may now be poised to take on an even broader role in preventing neurodegenerative diseases. As Dr. Reddin concluded, 'This research marks a significant advancement in how we understand the brain benefits of diabetes medications.' This article is based on findings from a study published in JAMA Neurology (July 2024). While the research links GLP-1 drugs like Ozempic and Mounjaro to reduce dementia risk, it is observational and does not prove direct causation. Further studies are needed. Always consult a healthcare provider before making medication decisions. Also Read | 5 coffee routine habits that could be doing more harm than good, say experts
